Carpenter D - Search Results

1

Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results.

Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Hwang TJ, et al. Among authors: carpenter d. JAMA Intern Med. 2016 Dec 1;176(12):1826-1833. doi: 10.1001/jamainternmed.2016.6008. JAMA Intern Med. 2016. PMID: 27723879

2

Tobacco industry response to a ban on lights descriptors on cigarette packaging and population outcomes.

Alpert HR, Carpenter D, Connolly GN. Alpert HR, et al. Among authors: carpenter d. Tob Control. 2018 Jul;27(4):390-398. doi: 10.1136/tobaccocontrol-2017-053683. Epub 2017 Aug 4. Tob Control. 2018. PMID: 28778970

3

Warnings without guidance: patient responses to an FDA warning about ezetimibe.

Shrank WH, Choudhry NK, Tong A, Myers J, Fischer MA, Swanton K, Slezak J, Brennan TA, Liberman JN, Moffit S, Avorn J, Carpenter D. Shrank WH, et al. Among authors: carpenter d. Med Care. 2012 Jun;50(6):479-84. doi: 10.1097/MLR.0b013e31825517b6. Med Care. 2012. PMID: 22581012

4

Target small firms for antibiotic innovation.

Hwang TJ, Carpenter D, Kesselheim AS. Hwang TJ, et al. Among authors: carpenter d. Science. 2014 May 30;344(6187):967-9. doi: 10.1126/science.1251419. Science. 2014. PMID: 24876477 No abstract available.

5

Can expedited FDA drug approval without expedited follow-up be trusted?

Carpenter D. Carpenter D. JAMA Intern Med. 2014 Jan;174(1):95-7. doi: 10.1001/jamainternmed.2013.9202. JAMA Intern Med. 2014. PMID: 24165977 No abstract available.

6

Assessment of US pathway for approving medical devices for rare conditions.

Hwang TJ, Carpenter D, Kesselheim AS. Hwang TJ, et al. Among authors: carpenter d. BMJ. 2014 Jan 17;348:g217. doi: 10.1136/bmj.g217. BMJ. 2014. PMID: 24443478 Review. No abstract available.

7

Scott Gottlieb and the Credibility of U.S. Therapeutics.

Carpenter D. Carpenter D. N Engl J Med. 2017 Apr 13;376(15):e30. doi: 10.1056/NEJMp1701738. Epub 2017 Mar 29. N Engl J Med. 2017. PMID: 28402242 No abstract available.

8

A unique researcher identifier for the Physician Payments Sunshine Act.

Carpenter D, Joffe S. Carpenter D, et al. JAMA. 2011 May 18;305(19):2007-8. doi: 10.1001/jama.2011.651. JAMA. 2011. PMID: 21586717 Free PMC article. No abstract available.

9

Drug-review deadlines and safety problems.

Carpenter D, Zucker EJ, Avorn J. Carpenter D, et al. N Engl J Med. 2008 Mar 27;358(13):1354-61. doi: 10.1056/NEJMsa0706341. N Engl J Med. 2008. PMID: 18367738

10

Approval times for new drugs: does the source of funding for FDA staff matter?

Carpenter D, Chernew M, Smith DG, Fendrick AM. Carpenter D, et al. Health Aff (Millwood). 2003 Jul-Dec;Suppl Web Exclusives:W3-618-24. doi: 10.1377/hlthaff.w3.618. Health Aff (Millwood). 2003. PMID: 15506165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results